Elicera Therapeutics AB (SE:ELIC)
:ELIC
Top Page
Elicera Therapeutics AB
(ELIC)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr5.00
▼(-6.54% Downside)
Action:ReiteratedDate:03/10/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and declining equity despite zero debt). Technicals provide some offset via improving short-term momentum, while valuation contributes limited support due to negative earnings and no dividend data.
Positive Factors
Next-generation immuno-oncology R&D
Elicera’s focus on CAR‑T and oncolytic virus approaches aligns with structural growth in immuno‑oncology. These modalities carry high technical barriers and can create platform value and durable differentiation if clinical progress advances toward regulatory validation and commercialization.
Negative Factors
Persistent operating losses and negative cash flow
Consistent operating losses and negative operating/free cash flow indicate ongoing cash burn without self‑funding. Over 2–6 months this structural cash gap implies reliance on external financing, elevating dilution risk and potentially constraining development timelines if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Next-generation immuno-oncology R&D
Elicera’s focus on CAR‑T and oncolytic virus approaches aligns with structural growth in immuno‑oncology. These modalities carry high technical barriers and can create platform value and durable differentiation if clinical progress advances toward regulatory validation and commercialization.
Read all positive factors
Elicera Therapeutics AB (ELIC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr270.83M
Dividend YieldN/A
Average Volume (3M)134.24K
Price to Earnings (P/E)―
Beta (1Y)-0.20
Revenue GrowthN/A
EPS Growth52.96%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding48,535,545
10 Day Avg. Volume92,396
30 Day Avg. Volume134,243
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)10.19
Price to Sales (P/S)0.00
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Elicera Therapeutics AB Business Overview & Revenue Model
Company Description
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate ...
How the Company Makes Money
null...
Elicera Therapeutics AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 7.13M | 11.23M | 1.28M | 587.00 |
| Gross Profit | 0.00 | 7.13M | 11.22M | 1.28M | -11.19K |
| EBITDA | -17.40M | -16.82M | -17.09M | -19.43M | -13.11M |
| Net Income | -17.41M | -16.11M | -16.40M | -19.52M | -13.12M |
Balance Sheet | |||||
| Total Assets | 27.42M | 27.56M | 30.18M | 46.31M | 54.74M |
| Cash, Cash Equivalents and Short-Term Investments | 24.85M | 26.40M | 29.38M | 43.82M | 52.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.06M | 6.79M | 13.78M | 13.51M | 2.50M |
| Stockholders Equity | 23.36M | 20.77M | 16.40M | 32.80M | 52.24M |
Cash Flow | |||||
| Free Cash Flow | -21.55M | -23.46M | -14.92M | -8.57M | -14.29M |
| Operating Cash Flow | -21.55M | -23.46M | -14.92M | -8.57M | -14.29M |
| Investing Cash Flow | 1.00K | 0.00 | 483.17K | 0.00 | -1.00K |
| Financing Cash Flow | 20.00M | 20.48M | 0.00 | 0.00 | 55.12M |
Elicera Therapeutics AB Technical Analysis
Negative
5.35
Price Trends
5.57
Positive
5.63
Negative
5.84
Negative
Market Momentum
-0.05
Positive
48.86
Neutral
67.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ELIC, the sentiment is Negative. The current price of 5.35 is below the 20-day moving average (MA) of 5.74, below the 50-day MA of 5.57, and below the 200-day MA of 5.84, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 67.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ELIC.
Elicera Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ELIC
Elicera Therapeutics AB
5.58
2.78
99.29%
DE:5IU
Isofol Medical AB
0.04
-0.10
-68.35%
DE:6IRA
IRLAB Therapeutics AB Class A
0.14
-0.55
-80.26%
DE:99Z
Modus Therapeutics Holding AB
0.02
-0.03
-60.98%
DE:BTPC
Active Biotech AB
0.01
<0.01
20.00%
DE:1BD
Bio-Works Technologies AB
0.30
0.21
214.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.